Odonate therapeutics, inc. (ODT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating expenses:
Research and development

27,947

25,853

25,097

26,453

26,631

26,797

21,667

17,024

14,460

13,040

9,126

3,282

2,454

General and administrative

2,874

2,856

2,666

2,783

2,591

2,680

2,960

2,755

2,421

2,706

1,246

618

272

Total operating expenses

30,821

28,709

27,763

29,236

29,222

29,477

24,627

19,779

16,881

15,746

10,372

3,900

2,726

Loss from operations

-30,821

-28,709

-27,763

-29,236

-29,222

-29,477

-24,627

-19,779

-16,881

-

-10,372

-3,900

-

Interest income

658

858

1,136

534

577

-

701

389

-

-

-

-

-

Net loss

-30,163

-27,851

-26,627

-28,702

-28,645

-28,763

-23,926

-19,390

-16,881

-15,746

-10,372

-3,900

-2,726

Net loss per share:
Basic and diluted

-0.99

-0.86

-0.88

-1.15

-1.16

-1.18

-0.98

-0.79

-0.69

-1.00

-0.74

-0.31

-0.26

Weighted-average shares outstanding:
Basic and diluted

30,610

30,657

30,268

24,893

24,682

24,641

24,453

24,402

24,351

19,435

14,036

12,740

10,464